Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

被引：0
|
作者：
Sanchez Gonzalez, J. C. [1 ]
Nunez Garcia, B. [1 ]
Blanco Clemente, M. [1 ]
Calvo de Juan, V. [1 ]
Cantos Sanchez de Ibarguen, B. [1 ]
Mendez Garcia, M. [1 ]
Aguado Noya, R. [1 ]
Ruiz de Domingo, D. [1 ]
Gonzalez Sanchez, A. [1 ]
Provencio, M. [1 ]
机构：
[1] Hosp Univ Puerta Hierro, Majadahonda, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Immunotherapy; Advanced disease; Real World Data;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-06
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [41] Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB-IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative
    Soares, M. A. S.
    Antunes, L.
    Redondo, P.
    Borges, M.
    Hermans, R.
    Patel, D.
    Grimson, F.
    Munro, R.
    Chaib, C.
    Lacoin, L.
    Daumont, M.
    Penrod, J. R.
    O'Donnell, J. C.
    Bento, M. J.
    Goncalves, F. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 15 - +
  • [42] Improving Outcomes of Patients with Acute Coronary Disease in Real Life: The Case of Applying in Practice What We Already Know from Clinical Studies
    Garzon, Stefano
    Lemos, Pedro A.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2023, 120 (05)
  • [43] Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials
    Chen, Chen
    Wang, Zehua
    Qin, Yan-Ru
    CANCER MEDICINE, 2023, 12 (03): : 2262 - 2280
  • [44] Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
    Schuette, Wolfgang
    Tesch, Hans
    Buettner, Hartwig
    Krause, Thomas
    Soldatenkova, Victoria
    Stoffregen, Clemens
    BMC CANCER, 2012, 12
  • [45] Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
    Wolfgang Schuette
    Hans Tesch
    Hartwig Büttner
    Thomas Krause
    Victoria Soldatenkova
    Clemens Stoffregen
    BMC Cancer, 12
  • [46] Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients with non-small cell lung cancer (NSCLC)
    Kuruvilla, PG
    Krieger, H
    Zibdawi, L
    Meharchand, J
    Solow, H
    Leighl, N
    Chin, C
    Stewart, JA
    Hollen, PJ
    Gralla, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 745S - 745S
  • [47] The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration Medical Centers (VAMCs).
    Leuva, Harshraj
    Zhou, Mengxi
    Wilkerson, Julia
    Sigel, Keith
    Hsu, Ta-Chueh
    Aggen, David Henry
    Langhoff, Erik
    Park, Yeun-Hee Anna
    Bates, Susan Elaine
    Fojo, Antonio Tito
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI plus CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
    Nuccio, A.
    Salomone, F.
    Viscardi, G.
    Venanzi, F. M.
    Bulotta, A.
    Ogliari, F. R.
    Oresti, S.
    Riva, S. T.
    Mollica, L.
    Vigano, M. G.
    Passaretti, F.
    Ravasi, M.
    Papotto, L.
    Ferrara, M.
    Ricciuti, B.
    Veronesi, G.
    Cascone, T.
    Garassino, M. C.
    Torri, V.
    Ferrara, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S790 - S791
  • [49] Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
    Zackova, Daniela
    Klamova, Hana
    Dusek, Ladislav
    Muzik, Jan
    Polakova, Katerina Machova
    Moravcova, Jana
    Jurcek, Tomas
    Dvorakova, Dana
    Racil, Zdenek
    Pospisil, Zdenek
    Oltova, Alexandra
    Michalova, Kyra
    Brezinova, Jana
    Razga, Filip
    Doubek, Michael
    Cetkovsky, Petr
    Trneny, Marek
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 318 - 321
  • [50] Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England
    Rigney, U.
    Lock, K.
    Chen, C.
    Escriu, C.
    LUNG CANCER, 2019, 127 : S40 - S40
12345